3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Myeloproliferative Disorders
1
Myeloid Malignancy
1
MDS
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
154
Cyclophosphamide
116
fludarabine phosphate
109
fludarabine
68
Mycophenolic Acid
62
Whole-Body Irradiation
56
ibrutinib
46
Tacrolimus
46
Peripheral Blood Stem Cell Transplantation
44
Lenalidomide
43
Cyclosporine
36
Busulfan
35
Bendamustine Hydrochloride
34
Antilymphocyte Serum
31
ofatumumab
30
obinutuzumab
28
Melphalan
28
idelalisib
26
Alemtuzumab
26
Filgrastim
25
Methotrexate
23
venetoclax
22
Chlorambucil
21
Granulocyte Colony-Stimulating Factor
20
acalabrutinib
19
thymoglobulin
18
Cyclosporins
16
Sirolimus
15
Etoposide
15
Pentostatin
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
eprenetapopt
×
Clear all
NCT04419389
2025-03-17
R/R
Aprea Therapeutics
Phase 1/2
Terminated
1 enrolled
4 charts